Abstract
Antibodies for therapy and diagnostics form one of the fastest growing segments of the pharmaceutical market. The combination of hybridoma and recombinant DNA technologies have led to an increased production of monoclonal antibodies (MAbs), including fully human MAbs, that can be tailored for specific applications. With advances in imaging methods, MAbs are increasingly used os in vivo diagnostic tools. Therapeutic MAbs, used to treat cancer and autoimmune diseases, have proven beneficial in the clinic. An overview is presented of the history, current state and future perspectives of this emergent field.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 199-211 |
| Number of pages | 13 |
| Journal | Drugs of Today |
| Volume | 45 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2009 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Fundamentals of antibody-related therapy and diagnostics. / Albrecht, Huguette; Rodosevich, James A.; Babich, Michael.
In: Drugs of Today, Vol. 45, No. 3, 03.2009, p. 199-211.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Fundamentals of antibody-related therapy and diagnostics
AU - Albrecht, Huguette
AU - Rodosevich, James A.
AU - Babich, Michael
PY - 2009/3
Y1 - 2009/3
N2 - Antibodies for therapy and diagnostics form one of the fastest growing segments of the pharmaceutical market. The combination of hybridoma and recombinant DNA technologies have led to an increased production of monoclonal antibodies (MAbs), including fully human MAbs, that can be tailored for specific applications. With advances in imaging methods, MAbs are increasingly used os in vivo diagnostic tools. Therapeutic MAbs, used to treat cancer and autoimmune diseases, have proven beneficial in the clinic. An overview is presented of the history, current state and future perspectives of this emergent field.
AB - Antibodies for therapy and diagnostics form one of the fastest growing segments of the pharmaceutical market. The combination of hybridoma and recombinant DNA technologies have led to an increased production of monoclonal antibodies (MAbs), including fully human MAbs, that can be tailored for specific applications. With advances in imaging methods, MAbs are increasingly used os in vivo diagnostic tools. Therapeutic MAbs, used to treat cancer and autoimmune diseases, have proven beneficial in the clinic. An overview is presented of the history, current state and future perspectives of this emergent field.
UR - http://www.scopus.com/inward/record.url?scp=67749143885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67749143885&partnerID=8YFLogxK
U2 - 101358/dot20094531341343
DO - 101358/dot20094531341343
M3 - Article
C2 - 19436842
AN - SCOPUS:67749143885
VL - 45
SP - 199
EP - 211
JO - Drugs of Today
JF - Drugs of Today
SN - 1699-3993
IS - 3
ER -